The government has introduced a new Uniform Code for Pharmaceutical Marketing Practices aimed at promoting ethical conduct in the industry. This code mandates the establishment of Ethics Committees and the appointment of Ethics Officers by pharmaceutical companies. It also includes a structured complaint redressal system, self-declarations for compliance, and disclosure of marketing expenses.
The updated Uniform Code for Pharmaceutical Marketing Practices, implemented in 2024, supersedes the previous version from 2015. Minister of State for Chemicals and Fertilisers, Anupriya Patel, highlighted that the new code enhances regulations to ensure ethical marketing practices within pharmaceutical companies. This includes the formation of Ethics Committees, appointment of Ethics Officers, and a mechanism for addressing complaints.
Furthermore, the code outlines strict guidelines for interactions between pharmaceutical companies and healthcare professionals to govern promotional activities. Amendments made in 2025 streamlined implementation processes, requiring companies to submit annual statements on marketing expenses. The code prohibits the provision of gifts, monetary benefits, or hospitality to doctors and their families by pharmaceutical firms.
To enforce compliance, pharmaceutical companies must self-declare adherence to the code and disclose expenditures related to medical education events. The code establishes a two-tier complaint adjudication process, with the Department of Pharmaceuticals handling appeals, ensuring accountability and transparency in marketing practices.
